This acquisition displays Kumar’s continued funding in Anixa Biosciences (NASDAQ:), an organization specializing in pharmaceutical preparations. The transaction was accomplished on January 15, 2025. With a market capitalization of $71.8 million and a “Fair” monetary well being rating in line with InvestingPro, the corporate maintains a robust stability sheet with additional cash than debt. Uncover 8 extra key insights about ANIX with an InvestingPro subscription. With a market capitalization of $71.8 million and a “Fair” monetary well being rating in line with InvestingPro, the corporate maintains a robust stability sheet with additional cash than debt. Uncover 8 extra key insights about ANIX with an InvestingPro subscription.
This acquisition displays Kumar’s continued funding in Anixa Biosciences, an organization specializing in pharmaceutical preparations. The transaction was accomplished on January 15, 2025.
In different current information, Anixa Biosciences has made important strides in its most cancers analysis and monetary endeavors. The biotechnology agency reported a web lack of $3.1 million for the second fiscal quarter of 2024, lower than the projected lack of $3.5 million. In a bid to diversify its treasury, the corporate’s board has authorized an funding in , a transfer linked to its sturdy stability sheet and surplus money.
Anixa Biosciences has additionally made notable progress in its medical trials, efficiently dosing the primary affected person within the third cohort of their Part 1 trial of CAR-T remedy for ovarian most cancers. In collaboration with Cleveland Clinic, the corporate has proven promising ends in its Part 1 breast most cancers vaccine trial, with over 70% of sufferers exhibiting immune responses. A Part 2 trial is deliberate for 2025.
Notably, analysts from EF Hutton and H.C. Wainwright have initiated and maintained a Purchase ranking for Anixa Biosciences, respectively. The corporate additionally introduced a share repurchase program and added Dr. Sanjay Juneja to its Most cancers Business Advisory Board. Lastly, Anixa Biosciences has secured a Japanese patent for its breast most cancers vaccine know-how, additional enhancing its portfolio.
This text was generated with the assist of AI and reviewed by an editor. For extra data see our T&C.
